NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
Rhea-AI Summary
NEXGEL (NASDAQ:NXGL) appointed Dave Hazard as Vice President of Sales for its BIONX Surgical division, effective May 13, 2026. The role supports commercialization of the newly launched division formed through a transformative acquisition expected to scale revenue.
Hazard brings extensive orthopedic, spine, and biologics sales leadership experience and prior partnerships relevant to BIONX Surgical.
Positive
- Experienced sales leader with 13+ years in orthopedics, spine, and biologics
- Previously built a 400+ representative salesforce for Aurix wound care PRP products
- Led a biologics business generating over $50 million in annual revenue at Arthrex
- Appointment supports commercialization of BIONX Surgical after a transformative acquisition
- Existing relationship with Arthrex, a current strategic partner of BIONX Surgical
Negative
- None.
News Market Reaction – NXGL
In the May 13 session, NXGL declined 8.10%, reflecting a notable negative market reaction. Argus tracked a peak move of +4.6% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Earnings date notice | Neutral | -4.1% | Announcement of timing for first quarter 2026 financial results call. |
| May 06 | Board appointments | Positive | +1.6% | Strategic partner executives join board following $5.5M financing support. |
| Apr 27 | CFO appointment | Positive | -6.0% | New CFO to help integrate Celularity biomaterials acquisition and growth plans. |
| Apr 21 | Acquisition & launch | Positive | +15.9% | Closed Celularity deal, launched BioNX Surgical, projected revenue and profit lift. |
| Apr 17 | Shareholder call update | Neutral | -1.5% | Rescheduled update call focused on the Celularity transaction details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Strategic transactions and partnerships (e.g., Celularity acquisition) have coincided with positive moves, while leadership changes and routine notices have often seen negative or muted reactions.
Over recent months, NEXGEL has focused on transforming its business via the Celularity regenerative biomaterials acquisition, which launched the BioNX Surgical division and coincided with a 15.89% move higher. Board additions linked to a $5.5 million strategic investment also saw a modest gain. By contrast, CFO transitions and scheduling calls or earnings dates have aligned with share price weakness. Today’s BIONX Surgical sales leadership hire fits the broader theme of building out this newly acquired, growth-focused platform.
Key Terms
biologics medical
prp products medical
hydrogel products medical
orthobiologics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue
LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a key moment in the Company's commercial growth phase.
Adam Levy, Chief Executive Officer of NEXGEL, stated, “We are excited to welcome Dave to BIONX Surgical at a pivotal time in our growth phase. He has a proven ability to build scalable sales infrastructure and establish the kind of enterprise partnerships that drive repeatable revenue. His deep expertise in biologics, combined with a proven ability to build and lead high-performing sales teams will be instrumental as we scale our commercial operations for our newly formed BIONX Surgical division.”
Mr. Hazard most recently served at Nuo Therapeutics, Inc., where he spent four years successfully commercializing the Aurix wound care PRP products. During his tenure, he built a salesforce of more than 400 representatives and secured Smith+Nephew as a white label partner for the Centrio product line. His responsibilities also included marketing, product development, portfolio expansion, fundraising, and strategic partnerships.
Prior to Nuo Therapeutics, Mr. Hazard served as Regional Manager of Orthobiologics at Arthrex for more than five years, where he led and expanded a biologics business generating over
Mr. Hazard commented, “NEXGEL and BIONX Surgical have a world-class portfolio with several new exciting products in the pipeline. The leadership team has executed key strategic partnerships and product innovation, creating meaningful opportunities across multiple verticals. We are well positioned to serve patients across sports medicine, orthopedics, plastics, wound care, and others with our robust tissue and hydrogel products. I believe these advantages will drive strong adoption and propel BIONX Surgical to rapid success.”
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts.. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2025, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
